Relmada Therapeutics Inc (OTCMKTS:RLMD) announced that it would be represented at the BIO International Convention 2015, by the company CEO, Sergio Traversa. The company is at the clinical-stage at the moment and is developing treatments for chronic pain. His presentation would give an overview of the company to the participants. Additionally, the company has recently announced that it has successfully completed the phase-1 single ascending dose study for treatment of neuropathic pain.

The recent phase-1 trials revealed that d-Methadone is well tolerated in the body and a maximum tolerated dose for the drug was also found. However, the drug is still to undergo a multiple ascending dose study, which would begin in second half of 2015. It is expected that the drug would make to phase-2 of clinical trials by early 2016. Senior VP of RLMD, Dr. Richard Mangano, stated that there is a growing need for treatments with high tolerance, efficiency and long-term safety profiles. D-methadone has the potential to meet all these demands and provide quick relief from chronic neuropathic pain.

Additionally, the company’s portfolio expands to three more products under development. RLMD’s Mepigel is an orphan drug, which is derived from a local anesthetic known as mepivaccine. The BuTab, an oral dosage derived from opioid analgesic buprenorphine and LevoCap ER, an abuse resistant drug derived from levorphanol, also are part of the portfolio. The company’s aim is to utilize an international team of experts to reduce the risks and costs of clinical developments. Furthermore, the company only targets areas of high unmet medical needs.

Currently, BuTab is the only other drug that is due to begin phase-1 of clinical trials. The company has filed a CTA with Health Canada to begin trials in the region. RLMD already has received a no-objection-certificate from health Canada to begin trials. These would eventually lead to the design of phase-3 trials in the future.

Relmada Therapeutics Inc (OTCMKTS:RLMD) finished the June 26 session at a share price of $1.95, after adding $0.08 to its share value and trading 120,023 shares during the session.